Pipeline category Number of
programmes
In-market core inhaled 8
Generic partnering 8
Vectura enhanced therapies 3
Novel molecule partnering 3
  • Click here to reset your filters.
  • Generic partnering
  • Enhanced therapies
  • Novel molecule partnering

flutiform® breath-triggered

Approved


  • Partner: Mundipharma
  • Capability: Device and Formulation
  • Category: Generic partnering
  • Details: Asthma (EU)

flutiform®

In development


  • Partner: Mundipharma
  • Capability: Device and Formulation
  • Category: Generic partnering
  • Details: Asthma (China)

VR315

In development


  • Partner: Hikma
  • Capability: Device and Formulation
  • Category: Generic partnering
  • Details: Asthma/COPD (US)

VR4651

Phase II


  • Partner: Ablynx
  • Capability: Device
  • Category: Novel molecule partnering
  • Details: Respiratory Syncytial Virus Infection
    (1)Ablynx ALX‌-0171

QVM149

Phase III


  • Partner: Novartis
  • Capability: Formulation
  • Category: Novel molecule partnering
  • Details: Asthma (EU, RoW)

VR506

In development


  • Partner: Hikma
  • Capability: Device and Formulation
  • Category: Generic partnering
  • Details: Asthma (US)

VR730

In development


  • Partner: Hikma
  • Capability: Device and Formulation
  • Category: Generic partnering
  • Details: Asthma/COPD (US)

VR632

In development


  • Partner: Sandoz
  • Capability: Device and Formulation
  • Category: Generic partnering
  • Details: Asthma/COPD (EU)

VR2081

In development


  • Partner: Sandoz
  • Capability: Device and Formulation
  • Category: Generic partnering
  • Details: Asthma/COPD (US)

VR410

In development


  • Partner: Potential to partner
  • Capability: Device and Formulation
  • Category: Generic partnering
  • Details: COPD (US)

VR475

Phase III


  • Partner: Wholly owned (Vectura)
  • Capability: Device and Formulation
  • Category: Enhanced therapies
  • Details: Severe Adult Asthma (EU)

VR475

Phase I


  • Partner: Wholly owned (Vectura)
  • Capability: n/a
  • Category: Enhanced therapies
  • Details: Severe Adult Asthma (US)

VR647

Phase II


  • Partner: Wholly owned (Vectura)
  • Capability: Device and Formulation
  • Category: Enhanced therapies
  • Details: Paediatric Asthma (US)

VR736

Phase II


  • Partner: Ventalon
  • Capability: Device
  • Category: Novel molecule partnering
  • Details: Severe Influenza (Global)
No results found.

A simple, integrated and focused business model

Our business model leverages core formulation, device and development capabilities and balances risk and returns.